Recce is pleased to announce that in a test of efficacy, conducted in an independent and approved contract laboratory in the United States, RECCE antibiotic (at lower concentration) performed equally (in terms of number of surviving mice) or better (in terms of Health Score of the surviving mice) than a commercial antibiotic (chosen as it is a remaining antibiotic having efficacy against the superbug, Methicillin Resistant Staphylococcus aureus [MRSA]).
This confirms a comparable result in which RECCE antibiotic performed better, and reported in Appendix 3, page 39 of the Replacement Prospectus of 21 Sept. 2015.
In the test reported today, three groups of 10 mice were each infected with MSRA superbug:
- six mice treated with RECCE antibiotic survived
- six mice treated with commercial antibiotic (Oxacillin) survived
- four mice that had no treatment, only saline, survived
The test compared RECCE antibiotic at 132 mg/Kg of mouse—with the commercial antibiotic Oxacillin, the positive control antibiotic at a larger dose of 500 mg/Kg and saline negative control, over 8 days. The survival rates (after culling) of mice within the three groups, each of 10 mice, respectively—after infection with MRSA superbug, is shown.
Further, in the test reported, in terms of Health Score of the remaining (non-culled) mice, the RECCE antibiotic left more healthy mice.
The health of remaining mice was qualitatively assessed according to their appearance and behavior. Mice having a Health Score of 1 are rated healthy; those having a Health Score of 4 are rated unhealthy.